Sun Pharma warns U.S. pricing pressure to hit 2019 profit

By Zeba Siddiqui (Reuters) - India's largest drugmaker Sun Pharmaceutical Industries Ltd said on Friday it expects its 2019 revenue to come in short of analysts' expectations due to pricing pressure in its main market, the United States. Makers of generic drugs have seen poor sales as uncertainty grows in the global market for copycat drugs due to rising competition and pricing scrutiny in the world's largest healthcare market. The warning compounds problems at Sun, which has been struggling to get clearance for its factories that are under U.S

Reuters May 26, 2018 00:05:49 IST
Sun Pharma warns U.S. pricing pressure to hit 2019 profit

Sun Pharma warns US pricing pressure to hit 2019 profit

By Zeba Siddiqui

(Reuters) - India's largest drugmaker Sun Pharmaceutical Industries Ltd said on Friday it expects its 2019 revenue to come in short of analysts' expectations due to pricing pressure in its main market, the United States.

Makers of generic drugs have seen poor sales as uncertainty grows in the global market for copycat drugs due to rising competition and pricing scrutiny in the world's largest healthcare market.

The warning compounds problems at Sun, which has been struggling to get clearance for its factories that are under U.S. supply bans due to quality control failures.

It now plans to reduce its research spend on some generic drug projects that have become "unviable", Dilip Shanghvi, the company's founder and managing director, said on a conference call with analysts.

The move follows larger rival Teva Pharmaceutical Industries's statement earlier this month that it planned to reduce its U.S. generics business.

"As a large investor, I am also unhappy," said Shanghvi who, along with affiliated parties, owns a major stake in the company he founded in 1983.

"We re trying to get the (Halol) plant re-certified at the earliest. It's taking much longer," he said.

The world's fifth-largest generic medicines maker is pinning its hopes on the launch this year of three specialty drugs: Yonsa for a type of prostate cancer, another, named OTX101, to treat dry eye, and Ilumya for psoriasis.

"We want to find a new engine of growth and that is why we are investing in this," Shanghvi said, adding: "We will have to incur significant expenses for these important launches."

Thirty-six analysts polled by Reuters expect Sun's fiscal 2019 revenue to come in at 300.36 billion Indian rupees ($4.43 billion) - about 13 percent higher than the 264.89 billion rupees for 2018.

While fourth-quarter profit was better than expected, helped by an uptick in India and emerging markets, revenue in the United States, which accounts for almost 35 percent of the total, fell 3 percent, Sun said.

Rivals Dr. Reddy's Laboratories Ltd and Lupin Ltd reported weak March-quarter earnings this week, blaming pricing pressures.

($1 = 67.7800 Indian rupees)

(Reporting by Zeba Siddiqui in Mumbai and Arnab Paul in Bengaluru; Editing by Subhranshu Sahu and Louise Heavens)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

also read

France, Germany to agree to NATO role against Islamic State - sources
| Reuters
World

France, Germany to agree to NATO role against Islamic State - sources | Reuters

By Robin Emmott and John Irish | BRUSSELS/PARIS BRUSSELS/PARIS France and Germany will agree to a U.S. plan for NATO to take a bigger role in the fight against Islamic militants at a meeting with President Donald Trump on Thursday, but insist the move is purely symbolic, four senior European diplomats said.The decision to allow the North Atlantic Treaty Organization to join the coalition against Islamic State in Syria and Iraq follows weeks of pressure on the two allies, who are wary of NATO confronting Russia in Syria and of alienating Arab countries who see NATO as pushing a pro-Western agenda."NATO as an institution will join the coalition," said one senior diplomat involved in the discussions. "The question is whether this just a symbolic gesture to the United States

China's Xi says navy should become world class
| Reuters
World

China's Xi says navy should become world class | Reuters

BEIJING Chinese President Xi Jinping on Wednesday called for greater efforts to make the country's navy a world class one, strong in operations on, below and above the surface, as it steps up its ability to project power far from its shores.China's navy has taken an increasingly prominent role in recent months, with a rising star admiral taking command, its first aircraft carrier sailing around self-ruled Taiwan and a new aircraft carrier launched last month.With President Donald Trump promising a US shipbuilding spree and unnerving Beijing with his unpredictable approach on hot button issues including Taiwan and the South and East China Seas, China is pushing to narrow the gap with the U.S. Navy.Inspecting navy headquarters, Xi said the navy should "aim for the top ranks in the world", the Defence Ministry said in a statement about his visit."Building a strong and modern navy is an important mark of a top ranking global military," the ministry paraphrased Xi as saying.